Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.12.2016 | original article

Orosomucoid is an independent predictor of prognosis in chronic heart failure

verfasst von: Petra Kaplan, MD, Prof. Dr. Bojan Vrtovec, MD PhD, Assist. Prof. Borut Jug, MD PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2016

Einloggen, um Zugang zu erhalten

Summary Background Methods Results Conclusion

Heart failure is associated with low-grade inflammation. In the present study we sought to assess the prognostic impact of orosomucoid, a marker of inflammation, in outpatients with heart failure.
In outpatients with chronic heart failure (no change in clinical status and/or therapy >3 months prior to inclusion), baseline levels of orosomucoid were determined. Clinical follow-up was obtained and the rate of heart failure-related deaths and hospitalisations recorded.
A total of 134 patients (median age 71, 33.3 % female, mean left ventricular ejection fraction [LVEF] 36 %) were included. During a median follow-up of 695 (456–811) days, 54 patients (40.1 %) experienced an event. On Cox multivariate analysis, orosomucoid levels above the median (>497 mg/l) emerged as an independent predictor of prognosis (hazard ratio = 2.86, 95 % confidence interval 1.48–5.52 after adjusting for age, gender, ischaemic vs. non-ischaemic aetiology, LVEF, NT-proBNP and NYHA class).
Orosomucoid levels are an independent predictor of heart failure-related mortality and hospitalisations in patients with chronic heart failure.
Vorheriger Artikel Pulse contour cardiac output monitoring in acute heart failure patients
Nächster Artikel Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery
Literatur
1.
Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92(4):720–6.CrossRefPubMed
2.
Gottediener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart disease in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–37.CrossRef
3.
Velavan P, Khan NK, Goode K, et al. Predictors of short-term mortality in heart failure – insights from the Euro heart failure survey. Int J Cardiol. 2010;138(1):63–9.CrossRefPubMed
4.
Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75.CrossRefPubMed
5.
O’Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfuntion: The HF-ACTION predictive risk model. Circ Heart Fail. 2011;5(1):63–71.CrossRefPubMedPubMedCentral
6.
Jug B, Salobir BG, Vene N, et al. Interleukin-6 is a stronger prognostic predictor than high-sensitive C‑reactive protein in patients with chronic heart failure. Heart Vessels. 2009;24(4):271–6.CrossRefPubMed
7.
8.
Libert C, Brouckaert, Fiers W. Protection by alpha 1‑acid glycoprotein against tumor necrosis factor-induced lethality. J Exp Med. 1994;180(4):1571–5.CrossRefPubMed
9.
10.
Fournier T, Medjoubi-N N, Porquet D. Alpha-1 glycoprotein. Bba–protein Struct Mol. 2000;1482(1-2):157–71.CrossRef
11.
Christiansen MS, Iversen K, Larsen CT, et al. Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. Scand J Clin Lab Invest. 2009;69(2):272–81.CrossRefPubMed
12.
Sörensson J, Matejka GL, Ohlson M, Haraldson B. Human endothelium cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol. 1999;M276(2 Pt 2):H530–H534.
13.
Sörensson J, Ohlson M, Bjönson A, et al. Orosomucoid has c.AMP-dependent effect on human endothelial cells and inhibits the action of histamine. Am J Physiol. 2000;278(5):1725–31.
14.
Chu J, Kishion S, Nomura A, et al. Serum alpha 1‑acid glycoprotein, sialic acid and protein binding of disopyramid in normal subjects and cardiac patients. Acta Pharmacol Sin. 1997;18(5):408–10.
15.
Engstrom G, Hedblad B, Stanvenow L, et al. Fatality of future coronary events is related to inflammation-sensitive plasma proteins. Criculation. 2004;100(1):27–31.CrossRef
16.
Magid E, Guldager H, Hesse D, Skovdal Christiansen M. Monitoring urinary orosomucoid in acute inflammation: observation on urinary excretion of orosomucoid, albumin, alpha1-micro globulin and IgG. Clin Chem. 2005;51(11):2052–8.CrossRefPubMed
17.
Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis of advanced cancer: interleukin-6, C‑reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer. 2003;11(1):60–2.PubMed
18.
Henry OF, Blacher J, Verdavaine J, et al. Alpha I‑acid glycoprotein is an independent predictor of in-hospital death in the elderly. Age Ageing. 2003;32(1):37–42.CrossRefPubMed
19.
Carriere I, Dupuy A‑M, Lacroux A, et al. Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc. 2008;56(5):840–6.CrossRefPubMedPubMedCentral
20.
Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up. Diabetologia. 2005;48(2):386–93.CrossRefPubMed
21.
Engström G, Lind P, Hedblad B, et al. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002;105(22):2632–7.CrossRefPubMed
22.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29(19:2388–442.
23.
Kalousova M, Sulkova S, Fialova L, et al. Glycixidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:2577–81.CrossRefPubMed
24.
Araujo JP, Laurenco P, Rocha-Goncales, et al. Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol. 2011;146(3):359–63.CrossRefPubMed
25.
Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol. 2002;85(1):33–49.CrossRefPubMed
26.
Loncar G, Fulster S, Healing S von, Popovic V. Metabolism and the heart: an overview of muscle, fat and bone metabolism in heart failure. Int J Cardiol. 2013;162(2):77–85.CrossRefPubMed
27.
Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation. 2003;107(11):1486–91.CrossRefPubMed
28.
29.
Shantsilla E, Wrigley BJ, Blann AD, Gill PS, Lip GY. A contemporary view on endothelial dysfunction in heart failure. Eur J Heart J. 2012;14(8):873–81.CrossRef
30.
Marchant D, Boyd J, Lin D, et al. Inflammation in Myocardial Diseases. Circ Res. 2012;110(1):126–44.CrossRefPubMed
Metadaten
Titel
Orosomucoid is an independent predictor of prognosis in chronic heart failure
verfasst von
Petra Kaplan, MD
Prof. Dr. Bojan Vrtovec, MD PhD
Assist. Prof. Borut Jug, MD PhD
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-1034-5

Weitere Artikel der Ausgabe 23-24/2016

Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization

  • Open Access
  • original article

Veranstaltungen

  • mitteilungen der gesellschaft der ärzte in wien

Nonbacterial thrombotic endocarditis presenting as intracerebral hemorrhage

  • case report

Genetic testing of familial hypercholesterolemia in a real clinical setting

  • case report

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction

  • Open Access
  • original article

Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease

  • original article